

James M S Wason

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4641468/publications.pdf>

Version: 2024-02-01

139
papers

6,589
citations

186265

28
h-index

69250

77
g-index

143
all docs

143
docs citations

143
times ranked

13216
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011, 476, 214-219.	27.8	2,400
2	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	27.6	792
3	Adaptive designs in clinical trials: why use them, and how to run and report them. <i>BMC Medicine</i> , 2018, 16, 29.	5.5	398
4	What role for genetics in the prediction of multiple sclerosis?. <i>Annals of Neurology</i> , 2010, 67, 3-10.	5.3	196
5	Multi-armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and Challenges. <i>Statistical Science</i> , 2015, 30, 199-215.	2.8	188
6	Imaging breast cancer using hyperpolarized carbon-13 MRI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 2092-2098.	7.1	138
7	Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. <i>European Journal of Human Genetics</i> , 2009, 17, 1309-1313.	2.8	115
8	Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?. <i>Trials</i> , 2014, 15, 364.	1.6	113
9	Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process. <i>Trials</i> , 2020, 21, 694.	1.6	99
10	A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. <i>Statistics in Medicine</i> , 2014, 33, 2206-2221.	1.6	98
11	Optimal design of multi-arm multi-stage trials. <i>Statistics in Medicine</i> , 2012, 31, 4269-4279.	1.6	85
12	Effect of sleep deprivation and exercise on reaction threshold in adults with peanut allergy: A randomized controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1584-1594.e2.	2.9	84
13	Some recommendations for multi-arm multi-stage trials. <i>Statistical Methods in Medical Research</i> , 2016, 25, 716-727.	1.5	67
14	Simple MRI score aids prediction of dementia in cerebral small vessel disease. <i>Neurology</i> , 2020, 94, e1294-e1302.	1.1	67
15	Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): a pragmatic, randomised controlled, superiority trial. <i>Lancet Psychiatry</i> , 2018, 5, 119-133.	7.4	63
16	Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. <i>Annals of Oncology</i> , 2015, 26, 2113-2118.	1.2	59
17	The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. <i>BMJ</i> , 2020, 369, m115.	6.0	57
18	Confounding underlies the apparent month of birth effect in multiple sclerosis. <i>Annals of Neurology</i> , 2013, 73, 714-720.	5.3	55

#	ARTICLE	IF	CITATIONS
19	The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. <i>British Journal of Cancer</i> , 2013, 108, 1340-1347.	6.4	53
20	Stepped wedge cluster randomized controlled trial designs: a review of reporting quality and design features. <i>Trials</i> , 2017, 18, 33.	1.6	51
21	When to keep it simple – adaptive designs are not always useful. <i>BMC Medicine</i> , 2019, 17, 152.	5.5	44
22	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 483-497.	0.8	40
23	Response-Adaptive Randomization for Multi-arm Clinical Trials Using the Forward Looking Gittins Index Rule. <i>Biometrics</i> , 2015, 71, 969-978.	1.4	39
24	Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?. <i>Pharmaceutical Statistics</i> , 2018, 17, 182-197.	1.3	39
25	Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 217-223.	0.9	33
26	Biomarker-guided trials: Challenges in practice. <i>Contemporary Clinical Trials Communications</i> , 2019, 16, 100493.	1.1	32
27	Optimal multistage designs for randomised clinical trials with continuous outcomes. <i>Statistics in Medicine</i> , 2012, 31, 301-312.	1.6	31
28	Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis. <i>Pharmaceutical Statistics</i> , 2012, 11, 91-96.	1.3	30
29	A multi-stage drop-the-losers design for multi-arm clinical trials. <i>Statistical Methods in Medical Research</i> , 2017, 26, 508-524.	1.5	30
30	Oxygen therapy and inpatient mortality in COPD exacerbation. <i>Emergency Medicine Journal</i> , 2021, 38, 170-177.	1.0	29
31	Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. <i>BMC Medicine</i> , 2018, 16, 210.	5.5	28
32	Design of telehealth trials – Introducing adaptive approaches. <i>International Journal of Medical Informatics</i> , 2014, 83, 870-880.	3.3	27
33	A Bayesian adaptive design for biomarker trials with linked treatments. <i>British Journal of Cancer</i> , 2015, 113, 699-705.	6.4	26
34	Including non-concurrent control patients in the analysis of platform trials: is it worth it?. <i>BMC Medical Research Methodology</i> , 2020, 20, 165.	3.1	26
35	A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis. <i>Genes and Immunity</i> , 2010, 11, 660-664.	4.1	25
36	A General Framework for Two-Stage Analysis of Genome-wide Association Studies and Its Application to Case-Control Studies. <i>American Journal of Human Genetics</i> , 2012, 90, 760-773.	6.2	25

#	ARTICLE	IF	CITATIONS
37	Healthy Campus Trial: a multiphase optimization strategy (MOST) fully factorial trial to optimize the smartphone cognitive behavioral therapy (CBT) app for mental health promotion among university students: study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 353.	1.6	25
38	A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials. <i>American Statistician</i> , 2021, 75, 424-432.	1.6	25
39	Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Cancer Research</i> , 2021, 81, 6004-6017.	0.9	25
40	Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy. <i>Biostatistics</i> , 2022, 23, 120-135.	1.5	24
41	Ensuring that COVID-19 research is inclusive: guidance from the NIHR INCLUDE project. <i>BMJ Open</i> , 2020, 10, e043634.	1.9	24
42	A novel nano-iron supplement to safely combat iron deficiency and anaemia in young children: The IHAT-GUT double-blind, randomised, placebo-controlled trial protocol. <i>Gates Open Research</i> , 2018, 2, 48.	1.1	24
43	Minimizing the Maximum Expected Sample Size in Two-Stage Phase II Clinical Trials with Continuous Outcomes. <i>Journal of Biopharmaceutical Statistics</i> , 2012, 22, 836-852.	0.8	22
44	Controlling type I error rates in multi-arm clinical trials: A case for the false discovery rate. <i>Pharmaceutical Statistics</i> , 2021, 20, 109-116.	1.3	21
45	Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points. <i>European Journal of Cancer</i> , 2011, 47, 983-989.	2.8	20
46	Using continuous data on tumour measurements to improve inference in phase II cancer studies. <i>Statistics in Medicine</i> , 2013, 32, 4639-4650.	1.6	19
47	Confounding in association studies: month of birth and multiple sclerosis. <i>Journal of Neurology</i> , 2014, 261, 1851-1856.	3.6	19
48	The longitudinal effect of ejaculation on seminal vesicle fluid volume and whole-prostate ADC as measured on prostate MRI. <i>European Radiology</i> , 2017, 27, 5236-5243.	4.5	18
49	Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-104.	2.8	18
50	HLA associations in South Asian multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 19-24.	3.0	17
51	Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): 5-year follow-up of a pragmatic, randomised, controlled, superiority trial. <i>Lancet Psychiatry</i> , 2020, 7, 420-430.	7.4	17
52	Imaging Glioblastoma Metabolism by Using Hyperpolarized [¹³ C]Pyruvate Demonstrates Heterogeneity in Lactate Labeling: A Proof of Principle Study. <i>Radiology Imaging Cancer</i> , 2022, 4, .	1.6	17
53	An adaptive design for updating the threshold value of a continuous biomarker. <i>Statistics in Medicine</i> , 2016, 35, 4909-4923.	1.6	16
54	Components of smartphone cognitive-behavioural therapy for subthreshold depression among 1093 university students: a factorial trial. <i>Evidence-Based Mental Health</i> , 2022, 25, e18-e25.	4.5	16

#	ARTICLE	IF	CITATIONS
55	Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. <i>British Journal of Cancer</i> , 2014, 110, 1950-1957.	6.4	15
56	Two-stage phase II oncology designs using short-term endpoints for early stopping. <i>Statistical Methods in Medical Research</i> , 2017, 26, 1671-1683.	1.5	15
57	Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. <i>Trials</i> , 2021, 22, 203.	1.6	15
58	Prediction of dementia using diffusion tensor MRI measures: the OPTIMAL collaboration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 14-23.	1.9	15
59	Evaluation of multisystemic therapy pilot services in the Systemic Therapy for At Risk Teens (START) trial: study protocol for a randomised controlled trial. <i>Trials</i> , 2013, 14, 265.	1.6	14
60	Improving the power of clinical trials of rheumatoid arthritis by using data on continuous scales when analysing response rates: an application of the augmented binary method. <i>Rheumatology</i> , 2016, 55, 1796-1802.	1.9	14
61	Planning multi-arm screening studies within the context of a drug development program. <i>Statistics in Medicine</i> , 2013, 32, 3424-3435.	1.6	13
62	Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothorax. <i>European Respiratory Journal</i> , 2015, 45, 1731-1734.	6.7	13
63	Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements. <i>Statistics in Medicine</i> , 2017, 36, 4616-4626.	1.6	13
64	Improving the analysis of composite endpoints in rare disease trials. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 81.	2.7	13
65	To add or not to add a new treatment arm to a multiarm study: A decision-theoretic framework. <i>Statistics in Medicine</i> , 2019, 38, 3305-3321.	1.6	13
66	Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine. <i>Rheumatology International</i> , 2021, 41, 1593-1600.	3.0	13
67	Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. <i>British Journal of Cancer</i> , 2011, 105, 766-772.	6.4	12
68	Risk in complex genetics: "All models are wrong but some are useful". <i>Annals of Neurology</i> , 2012, 72, 502-509.	5.3	12
69	A web application for the design of multi-arm clinical trials. <i>BMC Cancer</i> , 2020, 20, 80.	2.6	12
70	Identifying combined design and analysis procedures in two-stage trials with a binary end point. <i>Statistics in Medicine</i> , 2012, 31, 3874-3884.	1.6	11
71	Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter?. <i>Rheumatology</i> , 2022, 61, 1563-1569.	1.9	11
72	Two-stage penalized regression screening to detect biomarker-treatment interactions in randomized clinical trials. <i>Biometrics</i> , 2022, 78, 141-150.	1.4	11

#	ARTICLE	IF	CITATIONS
73	Evaluation of multisystemic therapy pilot services in Services for Teens Engaging in Problem Sexual Behaviour (STEPS-B): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 492.	1.6	10
74	Endoplasmic reticulum stress, unfolded protein response and development of colon adenocarcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 145-154.	2.8	10
75	Group sequential designs for stepped-wedge cluster randomised trials. <i>Clinical Trials</i> , 2017, 14, 507-517.	1.6	10
76	Blinded and unblinded sample size reestimation procedures for stepped-wedge cluster randomized trials. <i>Biometrical Journal</i> , 2018, 60, 903-916.	1.0	10
77	Mentalization for Offending Adult Males (MOAM): study protocol for a randomized controlled trial to evaluate mentalization-based treatment for antisocial personality disorder in male offenders on community probation. <i>Trials</i> , 2020, 21, 1001.	1.6	10
78	The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. <i>Trials</i> , 2020, 21, 528.	1.6	10
79	Use of an embedded, micro-randomised trial to investigate non-compliance in telehealth interventions. <i>Clinical Trials</i> , 2016, 13, 417-424.	1.6	9
80	Multi-arm multi-stage trials can improve the efficiency of finding effective treatments for stroke: a case study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 215.	1.7	9
81	The impact of an epilepsy nurse competency framework on the costs of supporting adults with epilepsy and intellectual disability: findings from the EpAID study. <i>Journal of Intellectual Disability Research</i> , 2019, 63, 1391-1400.	2.0	9
82	Multiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT): study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e035947.	1.9	9
83	Prevalence of Multiplicity and Appropriate Adjustments Among Cardiovascular Randomized Clinical Trials Published in Major Medical Journals. <i>JAMA Network Open</i> , 2020, 3, e203082.	5.9	9
84	Sequential multiple assignment randomized trial studies should report all key components: a systematic review. <i>Journal of Clinical Epidemiology</i> , 2022, 142, 152-160.	5.0	9
85	The role of comorbidities alongside patient and disease characteristics in long-term disease activity in RA using UK inception cohort data. <i>Rheumatology</i> , 2022, 61, 4297-4304.	1.9	9
86	A review of statistical designs for improving the efficiency of phase II studies in oncology. <i>Statistical Methods in Medical Research</i> , 2016, 25, 1010-1021.	1.5	8
87	Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential. <i>BMC Rheumatology</i> , 2021, 5, 21.	1.6	8
88	Effects of Exercise and Sleep Deprivation on Reaction Severity During Oral Peanut Challenge: A Randomized Controlled Trial. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2404-2413.e1.	3.8	8
89	Comparison of multimarker logistic regression models, with application to a genomewide scan of schizophrenia. <i>BMC Genetics</i> , 2010, 11, 80.	2.7	7
90	Blinded and unblinded sample size reestimation in crossover trials balanced for period. <i>Biometrical Journal</i> , 2018, 60, 917-933.	1.0	7

#	ARTICLE	IF	CITATIONS
91	Familywise Error Control in Multi-Armed Response-Adaptive Trials. <i>Biometrics</i> , 2019, 75, 885-894.	1.4	7
92	Analysis of responder-based endpoints: improving power through utilising continuous components. <i>Trials</i> , 2020, 21, 427.	1.6	7
93	The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected. <i>Statistical Methods in Medical Research</i> , 2015, 24, 909-919.	1.5	6
94	Improving outcomes in adults with epilepsy and intellectual disability (EpAID) using a nurse-led intervention: study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2016, 17, 297.	1.6	6
95	An optimised multi-arm multi-stage clinical trial design for unknown variance. <i>Contemporary Clinical Trials</i> , 2018, 67, 116-120.	1.8	6
96	Admissible multiarm stepped-wedge cluster randomized trial designs. <i>Statistics in Medicine</i> , 2019, 38, 1103-1119.	1.6	6
97	Determining the OPTIMAL DTI analysis method for application in cerebral small vessel disease. <i>NeuroImage: Clinical</i> , 2022, 35, 103114.	2.7	6
98	Employing a latent variable framework to improve efficiency in composite endpoint analysis. <i>Statistical Methods in Medical Research</i> , 2021, 30, 702-716.	1.5	5
99	OptGS: AnRPackage for Finding Near-Optimal Group-Sequential Designs. <i>Journal of Statistical Software</i> , 2015, 66, .	3.7	5
100	Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trials. <i>Statistics in Medicine</i> , 2022, , .	1.6	5
101	Capturing the real-world benefit of residual $\hat{\rho}^2$ cell function during clinically important time-periods in established Type 1 diabetes. <i>Diabetic Medicine</i> , 2022, 39, e14814.	2.3	5
102	Reducing the average number of patients needed in a phase II trial through novel design. <i>Clinical Research and Regulatory Affairs</i> , 2013, 30, 47-54.	2.1	4
103	The power of phase II end-points for different possible mechanisms of action of an experimental treatment. <i>European Journal of Cancer</i> , 2015, 51, 984-992.	2.8	4
104	Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project. <i>BMC Medicine</i> , 2021, 19, 251.	5.5	4
105	Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis. <i>Neurology</i> , 2022, 98, 754-764.	1.1	4
106	Adaptive Designs: Benefits and Cautions for Neurosurgery Trials. <i>World Neurosurgery</i> , 2022, 161, 316-322.	1.3	4
107	Comment on: Month of birth and risk of multiple sclerosis: confounding and adjustments. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 375-375.	3.7	3
108	Design of experiments for a confirmatory trial of precision medicine. <i>Journal of Statistical Planning and Inference</i> , 2019, 199, 179-187.	0.6	3

#	ARTICLE	IF	CITATIONS
109	Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies. <i>BMJ Open Ophthalmology</i> , 2019, 4, e000257.	1.6	3
110	Developing and testing high-efficacy patient subgroups within a clinical trial using risk scores. <i>Statistics in Medicine</i> , 2020, 39, 3285-3298.	1.6	3
111	Efficient analysis of time-to-event endpoints when the event involves a continuous variable crossing a threshold. <i>Journal of Statistical Planning and Inference</i> , 2020, 208, 119-129.	0.6	3
112	Developing a composite outcome measure for frailty prevention trials – rationale, derivation and sample size comparison with other candidate measures. <i>BMC Geriatrics</i> , 2020, 20, 113.	2.7	3
113	Multisystemic therapy compared with management as usual for adolescents at risk of offending: the START II RCT. <i>Health Services and Delivery Research</i> , 2020, 8, 1-114.	1.4	3
114	Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials. <i>BMC Cancer</i> , 2022, 22, 111.	2.6	3
115	Bayesian Sample Size Determination Using Commensurate Priors to Leverage Preexperimental Data. <i>Biometrics</i> , 2023, 79, 669-683.	1.4	3
116	A comparison of bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. <i>Trials</i> , 2013, 14, .	1.6	2
117	Group sequential crossover trial designs with strong control of the familywise error rate. <i>Sequential Analysis</i> , 2018, 37, 174-203.	0.5	2
118	Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 360-374.	0.8	2
119	Overestimated treatment effects in randomised phase II trials: What's up doctor?. <i>European Journal of Cancer</i> , 2019, 123, 116-117.	2.8	2
120	A latent variable model for improving inference in trials assessing the effect of dose on toxicity and composite efficacy endpoints. <i>Statistical Methods in Medical Research</i> , 2020, 29, 230-242.	1.5	2
121	Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods. <i>Pharmaceutical Statistics</i> , 2021, 20, 990-1001.	1.3	2
122	Bayesian design and analysis of external pilot trials for complex interventions. <i>Statistics in Medicine</i> , 2021, 40, 2877-2892.	1.6	2
123	Developing a predictive signature for two trial endpoints using the cross-validated risk scores method. <i>Biostatistics</i> , 2023, 24, 327-344.	1.5	2
124	Response adaptive intervention allocation in stepped-wedge cluster randomized trials. <i>Statistics in Medicine</i> , 2022, 41, 1081-1099.	1.6	2
125	Sample size estimation using a latent variable model for mixed outcome – primary, multiple primary and composite endpoints. <i>Statistics in Medicine</i> , 2022, 41, 2303-2316.	1.6	2
126	Optimal design for multi-arm multi-stage clinical trials. <i>Trials</i> , 2011, 12, .	1.6	1

#	ARTICLE	IF	CITATIONS
127	Using continuous data on tumour measurements to improve inference in phase II cancer studies. <i>Trials</i> , 2013, 14, .	1.6	1
128	Graphical approaches for the control of generalized error rates. <i>Statistics in Medicine</i> , 2020, 39, 3135-3155.	1.6	1
129	Exact group sequential designs for two-arm experiments with Poisson distributed outcome variables. <i>Communications in Statistics - Theory and Methods</i> , 2021, 50, 18-34.	1.0	1
130	Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and U.K. phase I/II trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 4531-4531.	1.6	1
131	Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials. <i>British Journal of Cancer</i> , 2022, 126, 204-210.	6.4	1
132	P198 The role of comorbidities alongside patient and disease characteristics on long-term disease activity in RA using UK inception cohort data. <i>Rheumatology</i> , 2022, 61, .	1.9	1
133	Subgroup analyses in randomised controlled trials frequently categorised continuous subgroup information. <i>Journal of Clinical Epidemiology</i> , 2022, , .	5.0	1
134	Group Sequential Clinical Trial Designs for Normally Distributed Outcome Variables. <i>The Stata Journal</i> , 2018, 18, 416-431.	2.2	0
135	A two-stage drop-the-losers design for time-to-event outcome using a historical control arm. <i>Pharmaceutical Statistics</i> , 2022, 21, 268-288.	1.3	0
136	Recent Developments in Group-Sequential Designs. , 2014, , 97-118.		0
137	Discussion on "Adaptive enrichment designs with a continuous biomarker" by Nigel Stallard. <i>Biometrics</i> , 2023, 79, 23-25.	1.4	0
138	When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay. <i>European Journal of Cancer</i> , 2022, 166, 270-278.	2.8	0
139	Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial. <i>BMC Rheumatology</i> , 2021, 5, 54.	1.6	0